SAN DIEGO, June 1, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in June, including:
Boston CEO Conference
Punit Dhillon, President and CEO, will moderate an expert panel entitled "Advances in Personalized Medicine" at the Boston CEO Conference on June 1 at 8:50 AM ET at the Four Seasons Hotel in Boston.
Boston CEO is a networking forum for industry CEOs and decision makers in the life sciences industry. Attendees gain insights from presentations and panels featuring CEOs from several of the world's leading biopharmaceutical companies. Industry leaders in venture capital and private equity also participate. For more information, please visit: https://bbbiotechconference.com/.
Sachs 2nd Annual Immuno-Oncology: BD&L and Investment Forum
Mr. Dhillon will present a corporate overview at the Sachs 2nd Annual Immuno-Oncology: BD&L and Investment Forum on June 3 at 3:30 PM CT at the Hyatt Chicago Magnificent Mile in Chicago. An archived version of the webcast will be available shortly after the presentation for 90 days on OncoSec's website: http://www.oncosec.com.
This forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical and biotech industries to facilitate partnering, funding, and investment. The forum attracts about 250 delegates and 30 presentations by listed and private biotechnology companies seeking licensing and investment. Numerous networking opportunities are available for on-site attendees. For more information, please visit: http://www.sachsforum.com/.
EUROGIN 2016 Conference
Robert H. Pierce, MD, Chief Scientific Officer, will present a lecture entitled: "Intratumoral IL-12 Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC)" during the "Updates on Immunotherapy Trials in HPV-HNSCC" session at the EUROGIN 2016 Conference on June 16 at 4:15 PM CEST at the Salzburg Congress in Salzburg, Austria.
This conference focuses on human papillomavirus infection and related cancers and fosters multidisciplinary interactions that are vital to making critical discoveries. The conference is aimed at developing a full review of current scientific developments in the field of cancer and human papillomavirus related diseases, raising the public health profile, and increasing the need for responsible health services. The program also encompasses state-of-the art science on ano-genital and head and neck cancer and provides forums to share expertise and learn from the leading experts in these fields. For more information, please visit: http://www.eurogin.com/2016/.
AACR Special Conference on Engineering and Physical Sciences in Oncology
Richard Connolly, PhD, and Arya Bahrami, PhD, members from OncoSec's Discovery Research team, will present advancements in gene electrotransfer for immunotherapy in two poster presentations at the AACR Special Conference on Engineering and Physical Sciences in Oncology. Results from abstracts entitled "Feedback Optimized Gene Electrotransfer for Immunotherapy" (#B32) and "A Novel Applicator for Endoscopic Gene Electrotransfer" (#B26) will be presented on June 27 from 5:00 – 7:00 pm ET in the Galleria Hall at the Westin Boston Waterfront in Boston.
This first AACR Special Conference will celebrate the advances made at the interface of engineering/physical sciences and oncology and explore the new frontiers in this emerging multidisciplinary field. The conference focuses on the contributions from engineers and physical scientists who have influenced all aspects of cancer biology, from quantitative understanding of tumor growth and progression to improved detection and treatment of cancer. For more information, please visit: http://www.aacr.org/meetings/.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in clinical development for several indications, including metastatic melanoma and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
CONTACT:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
SOURCE OncoSec Medical Incorporated